GBT is advancing a strategic drug discovery, development and commercialization approach that leverages the team’s expertise in blood biology. In doing so, we are building a multi-product pipeline comprised of novel medicines for grievous blood-based disorders.

Beyond our lead program in SCD, we plan to develop GBT440 as a potential therapeutic for acute and chronic hypoxemic pulmonary disorders, including idiopathic pulmonary fibrosis (IPF) and acute respiratory distress syndrome (ARDS). These are conditions in which the lungs cannot supply adequate oxygen to the blood. Currently, patients are treated with supplemental oxygen therapy, which is a well-established lifesaving treatment but also associated with a number of risks, including injury or infection as a result of intubation. A drug that has the potential to improve oxygen uptake and delivery, thereby providing benefits similar to oxygen therapy without the associated risks, could fill a significant unmet medical need.